Related Experiment Video
Updated: Jun 10, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
Kuo-Kai Chin1, Andriy Derkach2, Christopher Famulare1
1Leukemia Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
None:
Hypomethylating agents (HMA) and venetoclax (VEN) are commonly used in patients with IDH-mutated (IDHm) acute myeloid leukemia (AML) ineligible for induction chemotherapy. While prior studies demonstrated high response and survival rates with HMA/VEN in IDHm AML, the impact of treatment modifications in real-world settings is unclear. We retrospectively reviewed 89 IDHm AML patients treated with HMA/VEN from January 2018 to June 2023. CR/CRi rates were 76% in newly diagnosed (ND) and 55% in relapsed/refractory (R/R) patients, and median overall survival was 29.2 months (ND) and 17.1 months (R/R), respectively. Treatment modifications were common. Early VEN reductions were associated with lower response rates but not worse survival. Prolonged cycles were not associated with worse response rates or survival. Significant neutropenia and ED visits or unplanned hospitalizations were considerable before and after CR/CRi, though febrile neutropenia decreased afterward. HMA/VEN is efficacious, with treatment modifications not affecting survival, though long-term toxicities are notable.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Heart Failure V: Medical Management
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Myocarditis IV: Nursing Management

